Astepro is Safe and Appropriate for Patients with CKD and a Single Kidney
Astepro (azelastine) nasal spray is an excellent choice for your patient with chronic kidney disease and a single kidney who has seasonal allergies, as it has no renal contraindications and minimal systemic absorption.
Why Astepro Works Well in Renal Disease
Intranasal azelastine is administered topically with targeted delivery to nasal tissues, resulting in approximately 40% systemic bioavailability 1. Importantly, the FDA labeling for Astepro lists no contraindications whatsoever 2, including no restrictions for patients with renal impairment. This makes it particularly advantageous compared to systemically absorbed oral antihistamines that may require dose adjustments in CKD.
Treatment Efficacy and Positioning
According to the 2017 Joint Task Force guidelines, intranasal antihistamines like azelastine are effective first- or second-line therapy for seasonal allergic rhinitis 3. While intranasal corticosteroids remain the most effective single agent, azelastine offers several advantages:
- Rapid onset of action (benefit within 2 hours) 1
- Superior efficacy for nasal congestion compared to oral antihistamines 2
- Effective even in patients who failed oral antihistamine therapy 4
- Comparable efficacy to fluticasone propionate in moderate-to-severe disease 5
Practical Dosing for Your Patient
For adults with seasonal allergies, Astepro 0.15% solution can be dosed flexibly 6:
- Once daily: 2 sprays per nostril, OR
- Twice daily: 1-2 sprays per nostril every 12 hours
- Maximum: 4 sprays per nostril in 24 hours
No dose adjustment is needed for renal impairment.
Common Pitfalls to Avoid
The most frequent side effect is bitter taste (2.1-13.5% of patients), which is largely technique-dependent 3. Instruct your patient to:
- Spray away from the nasal septum
- Avoid tilting head back immediately after administration
- Consider the 0.15% formulation with sorbitol and sucralose added to improve taste 2
Somnolence rates are low (0.4-3%), comparable to placebo 3, 2, making concerns about sedation in CKD patients largely unfounded.
When to Consider Combination Therapy
If monotherapy with Astepro provides insufficient symptom control, the 2017 guidelines support adding an intranasal corticosteroid. The combination of azelastine plus fluticasone propionate showed greater symptom reduction than either agent alone (>40% relative improvement) 3. However, start with Astepro monotherapy first, as it may provide adequate relief without the need for corticosteroids.
Key Advantage Over Alternatives
Unlike oral antihistamines that undergo hepatic metabolism and renal excretion (potentially problematic in CKD), or intranasal corticosteroids that some patients don't tolerate, Astepro provides localized therapy with minimal systemic effects and no renal safety concerns. This makes it particularly well-suited for your patient's clinical scenario 2, 7.